Background: Mutations in the Plasmodium falciparum k13 gene are associated with artemisinin (ART) resistance. However, it is unclear whether the F446I mutation, the most prevalent allele at the China-Myanmar border and north of Myanmar, is associated with ART resistance. Therefore, the aim of this study was to investigate the role of this mutation in ART resistance by generating transgenic parasites expressing the F446I mutant allele.
Background
Artemisinin (ART) is a quick, effective anti-malarial drug that was discovered in China [1, 2] . Since ARTbased combination therapies were recommended by the World Health Organization (WHO) as a first-line treatment of malaria in 2005, the global malaria burden has significantly declined [3] . However, in 2008, ART resistance was reported in Plasmodium falciparum parasites in western Cambodia; a delay in clearance time was observed in infected patients who had received the standard 3-day treatment [4, 5] . The resistance has spread across the mainland of Southeast Asia, including Cambodia, Thailand, Vietnam, Myanmar, and China-Myanmar border areas [6, 7] . The spread of ART resistance, particularly in Africa, will certainly threaten global malaria control programmes. Therefore, efficient tools, such as molecular markers, for the detection and surveillance of ART-resistant parasites are urgently required to contain the spread of the resistance.
Currently, tools available for the detection and surveillance of ART-resistant malaria parasites include measurement of in vivo parasite clearance rates and ring-stage survival assay of 0-3 h (RSA 0-3 h ) that is well correlated with in vivo parasite clearance rates [8] . The K13 propeller gene of P. falciparum (k13; PF3D7_1343700) has been identified as a molecular marker for monitoring ARTresistant parasites [9] . A single mutation after position 440 in k13 is associated with slow parasite clearance rates in vivo and high parasite survival rates in vitro [7, 10] . The prevalent mutant alleles of k13 in the Thai-Cambodian/Thai-Myanmar border areas are C580Y, Y493H, R539T, and I543T, while that in the northern Myanmar and China-Myanmar border areas is F446I [7, 9, 11] . Mutant alleles such as C580Y and R539T have been confirmed to be correlated to ART resistance characterized by long in vivo parasite clearance half-lives after ART treatment and high RSA 0-3 h survival rates [9, 12] . In addition, the association of the C580Y mutation with ART resistance was also confirmed through introduction of the mutation into k13 [13] . However, F446I is the most prevalent mutant allele of k13 at the China-Myanmar border and in northern Myanmar. Previous study reported that of 392 isolates from the China-Myanmar border, 128 had the F446I mutation with a prevalence of 32.7% [11] . Two other studies showed the F446I mutation with a prevalence of 36.5 and 27.2% in this area [14, 15] . It is unclear whether this mutation is associated with ART resistance. Therefore, homology recombinant technology was used to introduce the F446I mutation in k13 gene of 2 distinct laboratory strains, 3D7 and FCC1/HN, of P. falciparum and investigate the impact of the mutation on ART susceptibility.
Methods

Parasite culture
The parasite culture was maintained in vitro in RPMI 1640 (Sigma-Aldrich, USA) with 10 mM HEPES (Invitrogen, California), 20 μg/ml hypoxanthine (Sigma-Aldrich, USA), 50 μg/ml gentamicin (Sigma-Aldrich, USA), 0.17% NaHCO 3 (Sigma-Aldrich, USA), and 5 mg/ml Albu-MAXII (Gibco, USA). Plasmodium falciparum lines were propagated in human O + erythrocytes (obtained from Changhai Hospital) and maintained at 37 °C in 5% CO 2 and 90% N 2 . The parasites were synchronized using 5% d-sorbitol, as described previously [16] . Briefly, the cultured parasites were pelleted and treated with sorbitol at room temperature for 15 min and washed with nonserum RPMI1640 medium and maintained in standard culture medium.
Construction of the pARL-PfK13
F446I and pARL-PfK13
C580Y
recombinant plasmids
The pARL-GFP plasmid containing the drug screening gene hDHFR was used to construct the pARL-PfK13
F446I
and pARL-PfK13 C580Y recombinant plasmid. The fulllength k13 gene with F446I mutation and 1563 bp of the C-terminal of k13 gene was amplified using overlapping PCR. The primers for amplifying fragments with F446I were as follows: 1350 bp 5′-terminal fragment was amplified by primer pair of PARL-F (GCagatctATG GAA   GGA GAA AAA GTA AAA ACA AAAG) and K13-446-R  (TCC ACC TAT ACA AAT TAC TAA TGG G); while 831 bp  3′-terminal fragment was amplified by primer pair of  K13-446-F  (CCC ATT AGT AAT TTG TAT AGG TGG A) and PARL-R (GCggtaccTTA TAT ATT TGC TAT TAA AAC GGA GTG). The two fragments were combined by PCR through overlapping sequences to generate the full length k13 gene with F446I mutation by primer pair of PARL-F and PARL-R. Similar strategy was used to generate the1563 fragment of k13 gene with C580Y mutation: the 1128 bp upstream fragment was amplified by primer pair of PARL-A-F (GCagatctAAC GGA ATT AAG TGA TGC TAGTG) and K13-580-R (AGC AAC ATA CAT AGC TGA TGA) while the 435 bp downstream fragment by K13-580-F (GCT ATG TAT GTT GCT TTT GAT) and PARL-R. The resulting fragments were cloned into the pARL-GFP plasmid by using the restriction sites BglII and KpnI (Fermentas, USA) to generate recombinant plasmids of pARL-PfK13 F446I and pARL-PfK13
C580Y
. The recombinant plasmids were purified using the Endo Free Plasmid Maxi Kit (Qiagen, Germany).
Parasite transfection
Synchronous P. falciparum 3D7 and FCC1/HN (isolated from Hainan Province and established for in vitro continuous cultivation in 1978) parasites were transfected with the recombinant plasmids as described previously [17] . Briefly, P. falciparum parasite culture with a high synchronous ring stage was prepared at 5% parasitaemia. 270 μl Cytomix buffer (120 mM KCl, 10 mM KH 2 PO 4 , 25 mM HEPES, 2 mM EGTA, 0.15 mM CaCl 2 , and 5 mM MgCl 2 ) was mixed with 100 μg of the plasmid, and then with 50% haematocrit of the infected erythrocytes. The mixture was transferred to a 0.2-cm cuvette (Bio-Rad) and electroporated using the Bio-Rad MicroPulser with voltage 310 V and 950 μF. The transfected culture was selected using 2.5 nM WR99210 (Jacobus Pharmaceuticals) after 48 h until the WR99210-resistant parasites were obtained. DNA was extracted using QIAmp Mini kits (Qiagen, Germany) and detected by PCR using primers hDHFR, P3/P4, P4/P5, and P3/P6. The primers for identification of transfected parasites were as follows: hDHFR-F: TTA ATG TAT TAT TCC AAT GTG CAT GAT, hDHFR-R: GTA CTT AAT GCC TTT CTC CTC CTG; P3: ACC ATG ATT ACG CCA AGC; P4: AAA ACG AAC ATT AAG CTG CC; P5: AAC AAG GCG TAA ATAT TCG TGT; P6: ATA AGA ACA TTT AAA ATT TCT TCA TT. The sequences of the modified k13 gene were confirmed by DNA sequencing. RNA extracted from the F446I mutant parasite was digested by DNaseI (Sigma-Aldrich, USA) for 15 min in room temperature before transcribed to cDNA. The full-length of k13 gene was amplified from the cDNA of F446I mutant parasite and subcloned to pEASY-T1 cloning Vector (purchased from Transgen Biotech, China). The primers for amplification were as follows: K13-F: ATG GAA GGA GAA AAA GTA AAA ACA AAAG; K13-R: TTA TAT ATT TGC TAT TAA AAC GGA GTG. The RNA of F446I mutant parasite after digestion was used as template to amplified k13 gene as a no-RT control. The k13 gene in the pEASY-T1-K13 recombinant plasmid was sequenced using the primers of M13 as follows: M13F-GTA AAA CGA CGG CCAGT; M13R-CAG GAA ACA GCT ATGAC.
Antibody and western blot
The antibody against k13 protein was produced by GenScript Corporation (USA). Briefly, a synthetic peptide (MEGEKVKTKANSISC) was conjugated with keyhole limpet haemocyanin and formulated with adjuvant. Rabbits were immunized for 4 times at 2-week intervals. The polyclonal antibodies were affinity-purified with peptides.
Western blot was performed as described previously [18] . Briefly, the parasite culture was pelleted and resuspended with 10 volumes of phosphate-buffered saline (PBS). Next, 3% saponin was added to lyse the erythrocytes at 0.03% final concentration on ice for 15 min, and the mixture was centrifuged. The pellets were washed 2 times with PBS and resuspended with a suitable volume of buffer A (20 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 50 mM NaCl, 0.65% NP-40, 1 mM DTT, and 1× protease inhibitor cocktail). The mixture was incubated for 1 h at 4 °C and centrifuged at 14,000 rpm to obtain the supernatant. The supernatant was separated by 10% SDS-PAGE gel and detected using PfK13 polyclonal antibody (1:200). The Actin (Abcamab40854) was used as the loading control (1:1000). The secondary antibody was IRDye800CW goat anti-rabbit (LI-COR) diluted at 1:5000.
RSA 0-3 h assay RSA 0-3 h was performed as described previously [8] . Briefly, P. falciparum parasites were synchronized 2 times with 5% sorbitol to obtain tightly synchronous early-ring stage. The initial culture was prepared at 1% parasitaemia and 2% haematocrit, and then was exposed to 700 or 20 nM DHA (Sigma-Aldrich, USA) for 6 h. Then, the culture mixture was washed 3 times with non-serum 1640 culture medium, and cultured again for 66 h. The viable parasites were counted using a microscope in Giemsastained thin smears. The survival rate was calculated using Ps/Pc × 100%, where Ps is the parasitaemia in the DHA treatment group, while Pc is the parasitaemia in the control group. The counting was performed by two different experienced laboratories. Each assay was repeated for 3 times independently, with each group setting three technical repetitions. Each technical repetition was counted for 40,000 erythrocytes.
Results
Generation of constructs for transfection of the parasites
To generate the recombinant plasmids for the transfection, the fragments of k13 gene were produced with either F446I or C580Y mutations by using PCR. For construction of the replacement F446I, 2 DNA fragments covering the entire k13 gene (2181 bp) were amplified from the genomic DNA of P. falciparum. The two fragments were combined using PCR with an overlapping sequence of 15 bp in which a point mutation of T to A was introduced, resulting in changes to the corresponding amino acid residue from phenylalanine (F) to isoleucine (I) (designated as PfK13 F446I mut gene). The full-length PfK13 . The substitution of T to A in the PfK13 F446I mut gene was verified by DNA sequencing. The overall strategy for the preparation of PfK13 F446I mut is outlined in Fig. 1a .
A similar strategy was used for the generation of the PfK13 C580Y mut gene. However, in this case, only a truncated k13 gene (1563 bp) was amplified instead of the full gene. This is because of the position of the C580Y mutation near the C-termini and that only a partial sequence of the gene is needed for single crossing-over recombination. Similarly, two fragments covering the truncated k13 gene were amplified and combined using PCR. A point mutation of G to A at nucleotide position 1739 was introduced through the overlapped neighbouring sequences of the 2 fragments, resulting in a change from cysteine (C) to tyrosine (Y) (designated as PfK13 C580Y gene).
Generation of transgenic parasites
Two distinct laboratory strains of P. falciparum, 3D7 (designated as 3D7 wt ) and FCC1/HN (FCC1/HN wt ), were used for the transfection. Parasites in the high synchronous ring stage were transfected with individual recombinant plasmids by electroporation, as described above (Fig. 1b) . The transfected culture was selected using 2.5 nM WR99210 at 48 h post-electroporation until the WR99210-resistant parasites were visible. Cloning of the resistant parasites was performed by limiting dilution. The resulting clones with the replacement F446I were designated as 3D7 F446I mut and FCC1/HN F446I mut lines (Fig. 1c) , and the clones with the replacement C580Y, as 3D7 C580Y mut and FCC1/HN C580Y mut lines (Fig. 1d) . The genomic DNA of each parasite clone was prepared for PCR verification of the integrations and mutant (Fig. 2b) . In addition, the fragments amplified by the primer pair P4/P5 were sequenced, and the correct substitution of A for T for the F446I mutation and A for G for the C580Y mutation was confirmed (Fig. 2c) .
As shown in Fig. 1c , the transgenic parasite with the F446I mutation has two full-length k13 coding sequences, the mutant and wild-type k13 alleles. To exclude the possibility that they are both expressed, we generated the full-length k13 cDNA from the 3D7 F446I mut parasite and Fig. 2 Verification of the integration of the F446I mutation into the target locus. a PCR amplification using the indicated primers produced the expected fragments in lanes 4, 5, 7, and 8 for the transgenic parasite lines, whereas no fragments were detected in the other lanes for the parent parasites. Lanes 1-9: negative control, pARL-K13 F446I . b PCR analysis showed that the expected fragments were amplified from the transgenic parasites. Lanes 1-9, as indicated above. c Sequencing verification of the mutations from T to A for F446I and G to A for C580Y subcloned the fragments into pEASY-T1 cloning vector for sequencing. As shown in result no k13 gene was amplified by PCR in the no-RT controls (Fig. 3a, lane  1) , indicating no contaminating of genomic DNA in the sample. 12 clones of the recombinant plasmids containing the k13 gene were sequenced across the F446I mutation. Sequencing data showed that all the 12 clones showed the F446I mutant alleles (none of them are wildtype), indicating that only the mutant allele is expressed.
To investigate whether the integration of the mutant alleles affected the expression of k13, the k13 expression of each transgenic parasite clone were determined with western blot. As shown in Fig. 3b, the Ring-stage survival of the transgenic parasites with the F446I mutation RSA 0-3 h was performed to evaluate the transgenic parasite lines expressing F446I and C580Y mutants of k13 for their susceptibility to DHA. First, ring survival rates of both transgenic parasites and their parent lines were measured when parasites were exposed to elevated concentrations of DHA. As shown in Fig. 4a , at the lowest concentration of DHA (i.e., 5.5 nM), no significant differences in the ring survival rates of the 3D7 wt and 3D7 F446I mut parasite lines were observed (p > 0.05), while at 11, 22, and 44 nM DHA, the ring survival rates of 3D7 F446I mut were significantly higher than that of 3D7 wt (p < 0.05, 0.01, and 0.001, respectively). At the concentrations beyond 44 nM, i.e., from 88 to 700 nM, no parasite was observed in the 3D7 wt parasite line, and different ring survival rates were detected in the 3D7 F446I mut line. A similar result was obtained for the FCC1/HN F446I mut line when compared with its parent parasite strain (Fig. 4b) . Then 2 DHA concentrations (i.e., 20 and 700 nM) from the above-mentioned experiment were selected to further measure the ring survival rates of the F446I and C580Y mutant parasite lines. No parasite of the wild type strain of 3D7 wt could survive (survival rate: 0) when 700 nM DHA was used, while the ring survival rates for the transgenic parasite lines of both 3D7 F446I mut and 3D7 C580Y mut were similar at 0.73 ± 0.10% and 0.91 ± 0.11%, respectively (Table 1) . However, when 20 nM DHA was used, both 3D7 F446I mut and 3D7 C580Y mut transgenic parasite lines showed high ring-survival rates at 26.0 ± 1.48% and 33.08 ± 1.20%, respectively, whereas the 3D7 wt parasites showed a significantly lower survival rate at 3.15 ± 0.13% (p < 0.05). Similar results were obtained after measuring the ring survival rates of FCC1/HN F446I mut and FCC1/ HN C580Y mut lines when compared with the FCC1/HN wt strain (Table 1) . F08-27 isolate of P. falciparum carrying the C580Y mutation collected from China to Myanmar border showed high RSA survival rates [11] and is used as a positive control in this study. The survival rate of the F08-27 isolate was 8.27 ± 0.63% and 65.8 ± 4.06% when the isolate was treated with 700 and 20 nM DHA, respectively. For generating transgenic 3D7 parasites with the F446I mutation, 7 clones were obtained by sub-cloning the WR99210-resistant parasite by limiting dilution. Then these clones were sequenced to confirm the presence of F446I. All the clones showed increased levels of ring survival from 17.6 to 29.5% at 20 nM DHA when compared with 3.15% survival of 3D7 wt (Fig. 5) . Interestingly, the survival rate of one clone, 3D7 F446I mut -F1, expressing the F446I mutant allele was 0 at 700 nM DHA, which is the same as the wild type of the strain. The survival rate was also lower than that of the other clones (17.6%) at 20 nM DHA. The sequencing of the PfK13 gene of the 3D7 (data not show). It is rare for multisite mutation to occur in k13 in field isolates. Further investigation is required to understand whether more than 1 mutation in k13 affects the ART susceptibility of the parasite.
Discussion
ART resistance is evaluated in vivo by delayed parasite clearance and in vitro by high ring survival rates with RSA 0-3 h [8] . The resistant phenotypes are strongly associated with a single mutation after amino acid position 440 in k13 [7, 10] . Some k13 mutations, such as C580Y, R539T, Y493H, and I543T, have been reported to be associated with the resistance of parasites to ART [9] , and they are highly prevalent in the border areas of Thai/Cambodia and Thai/Myanmar but rare north of Southeast Asia, including north of Myanmar and China-Myanmar border region [7, 19, 20] . Interestingly, north of Southeast Asia, the most prevalent mutant allele of k13 is F446I. In previous study, the result showed that the prevalence of this mutation is 32.7% in the China-Myanmar border area and this mutation was not detected in Thai/Cambodia and Thai/Myanmar border regions [11] . From 2009 to 2012, Huang et al. [15] conducted a therapeutic efficacy study of artesunate in the China-Myanmar border region and showed that the single mutation of F446I with a prevalence of 36.5% was significantly associated with prolonged parasite half-life and parasitaemia on day 3 after treatment. However, several other studies have found no correlation between this mutation and prolonged parasite clearance time [7, 21] ; however, the reason may be the small sample sizes. A previous study found that 2 of 3 parasites with this mutation showed a parasite clearance time < 5 h [22] . A recent study on the therapeutic efficacy of artemether-lumefantrine conducted in the northeast region of India also found no correlation of this mutation with delayed parasite clearance [23] .
In previous study, the ring survival rate of 27 isolates with F446I mutation were measured by using RSA 0-3 h . Of them, only 6 had a high ring survival rate (> P 95 value) that was defined as the association with delayed parasite clearance in vivo, and the ring survival rates of the other isolates were below the P 95 value. The statistical analysis indicated that the F446I mutant was not associated with high ring-stage survival. Thus, there is much debate on whether the F446I mutation is associated with ART resistance. In this study, F446I mutation in k13 was introduced to the ART-sensitive 3D7 and FCC1/HN strains, and the resulting transgenic parasite lines FCC1/HN F446I mut and 3D7 F446I mut showed increased ring survival rates at both 20 and 700 nM DHA concentrations. Moreover, the survival rates of the transgenic parasites with the F446I mutation were similar to those of the parasites with the C580Y mutation demonstrated to be correlated with ART resistance. Thus, the result suggested the F446I mutation may be associated with ART resistance.
The C580Y mutation in k13 is a primary marker for ART resistance and the most prevalent mutation in western Cambodia where the resistant parasite was first reported. Several transgenic parasite clones have been generated in which the C580Y mutation was introduced into the k13 gene of various parasite isolates by using the CRISPR-Cas9 technology or zinc-finger nucleases [10, 13] . These transgenic clones showed elevated ringstage survival when compared with their parent parasites; however, the ring survival rates of these transgenic parasite clones were variable. The 2 transgenic clones expressing k13 C580Y showed survival rates of 11-15%, while another transgenic FCB parasite clone expressing the C580Y allele showed a survival rate of 1.9% when compared with the survival rate of 0.3% in the parent FCB isolate. We generated both FCC1/HN C580Y mut and 3D7 C580Y mut transgenic lines that showed 0.63 ± 0.07% and 0.91 ± 0.11% RSA 0-3 h survival at 700 nM DHA concentration, whereas the survival rates of their parent parasites were 0%. Interestingly, when the DHA concentration reduced to 20 nM, both transgenic lines showed 17.5 ± 0.80% and 33.08 ± 1.20% survival rates, whereas their parent parasites showed only 2.86 ± 0.44% and 3.15 ± 0.13% survival rates, respectively. It could be concluded that the introduction of both C580Y and F446I mutations in k13 of 2 distinct laboratory parasite strains resulted in increased ring survival indicating that, similar to the C580Y substitution, F446I may play role in parasite response to ART. 
